Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Overall survival in patients with metastatic or locally advanced pancreatic cancer following chemoradiation with novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1- NK cell therapy.
Authors
Tara Elisabeth Seery
Hoag Cancer Center, Newport Beach, CA;
Tara Elisabeth Seery , Chaitali Singh Nangia , Phillip D. Reid , Bruno Fang , Heidi Ann McKean , Leonard S. Sender , Sandeep K. Reddy , Patrick Soon-Shiong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03563144
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 720)
DOI
10.1200/JCO.2023.41.4_suppl.720
Abstract #
720
Poster Bd #
L7
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Promising survival and disease control in third-line or greater metastatic or locally advanced pancreatic cancer patients following chemo-radiation and novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1- NK cell therapy.
First Author: Tara Elisabeth Seery
Poster
2021 ASCO Annual Meeting
A phase 2 study of cyclophosphamide (CY), GVAX, pembrolizumab (Pembro), and stereotactic body radiation (SBRT) in patients (pts) with locally advanced pancreas cancer (LAPC).
First Author: Valerie Lee
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Metronomic oral cyclophosphamide as maintenance therapy in metastatic pancreatic ductal adenocarcinoma.
First Author: Michele Reni
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Comparing the outcome of doublet therapy (gemcitabine and cisplatin) with triplet therapy (gemcitabine, cisplatin and nab paclitaxel) in locally advanced or metastatic gall bladder carcinoma patients: An open-label randomized control trial.
First Author: Chandrani Khatri